Table 1.
Demographics of subjects from the Amsterdam Dementia Cohort.
| Variable | Subjects included in LC-MS/MS discovery |
Subjects included in ELISA technical replication |
||||
|---|---|---|---|---|---|---|
| Low CSF pathology | High CSF pathology | P-value | Low CSF pathology | High CSF pathology | P-value | |
| N | 25 | 25 | / | 50 | 50 | / |
| CSF pathology = (373+0.82[tau])/[Aβ42] | 0.56 ± 0.05 | 3.63 ± 0.49 | <0.001∗ | 0.54 ± 0.05 | 3.45 ± 0.82 | <0.001∗ |
| Age (years) | 65.84 ± 3.80 | 65.01 ± 3.81 | 0.648 | 63.74 ± 4.51 | 64.21 ± 4.13 | 0.549 |
| Female gender N (%) | 10 (40) | 11 (44) | 0.777 | 21 (42) | 27 (54) | 0.232 |
| Clinical diagnosis | ||||||
| SCD N (%) | 16 (64) | 2 (8) | / | 41 (82) | 5 (10) | / |
| MCI N (%) | 8 (32) | 7 (28) | / | 8 (16) | 7 (14) | / |
| AD N (%) | 1 (4) | 16 (64) | / | 1 (2) | 38 (76) | / |
| APOE genotype 𝜀4+ N (%) | 6 (24) | 18 (72) | <0.01∗ | 16 (32) | 30 (60) | <0.01∗ |
| MMSE | 28 ± 2 | 25 ± 2 | <0.001∗ | 28 ± 2 | 22 ± 6 | <0.001∗ |
CSF, cerebrospinal fluid; SCD, subjective cognitive decline; MCI, mild cognitive impairment; AD, Alzheimer’s disease; APOE, apolipoprotein E; MMSE, mini-mental state examination. Mean ± SD. ∗Statistically significant.